JP7353973B2 - Ａｐｏｃ－ｉｉ模倣ペプチド - Google Patents

Ａｐｏｃ－ｉｉ模倣ペプチド Download PDF

Info

Publication number
JP7353973B2
JP7353973B2 JP2019539809A JP2019539809A JP7353973B2 JP 7353973 B2 JP7353973 B2 JP 7353973B2 JP 2019539809 A JP2019539809 A JP 2019539809A JP 2019539809 A JP2019539809 A JP 2019539809A JP 7353973 B2 JP7353973 B2 JP 7353973B2
Authority
JP
Japan
Prior art keywords
apoc
peptide
helix
certain embodiments
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019539809A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020511425A (ja
JP2020511425A5 (enExample
Inventor
リマリー，アラン，トーマス
ゴーシュ，ソウミトラ，シャンカー
デバララジャ，マハブ，エヌ．
ロ，チー－フン
スビリドフ，デニス，オー．
ウォルスカ，アンナ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of JP2020511425A publication Critical patent/JP2020511425A/ja
Publication of JP2020511425A5 publication Critical patent/JP2020511425A5/ja
Priority to JP2023100171A priority Critical patent/JP2023116739A/ja
Application granted granted Critical
Publication of JP7353973B2 publication Critical patent/JP7353973B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1722—Plasma globulins, lactoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/41—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a Myc-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/42—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a HA(hemagglutinin)-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2019539809A 2017-01-19 2018-01-19 Ａｐｏｃ－ｉｉ模倣ペプチド Active JP7353973B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023100171A JP2023116739A (ja) 2017-01-19 2023-06-19 Ａｐｏｃ－ｉｉ模倣ペプチド

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762448358P 2017-01-19 2017-01-19
US62/448,358 2017-01-19
US201762476535P 2017-03-24 2017-03-24
US201762476531P 2017-03-24 2017-03-24
US62/476,531 2017-03-24
US62/476,535 2017-03-24
PCT/US2018/014532 WO2018136803A1 (en) 2017-01-19 2018-01-19 Apoc-ii mimetic peptides

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023100171A Division JP2023116739A (ja) 2017-01-19 2023-06-19 Ａｐｏｃ－ｉｉ模倣ペプチド

Publications (3)

Publication Number Publication Date
JP2020511425A JP2020511425A (ja) 2020-04-16
JP2020511425A5 JP2020511425A5 (enExample) 2021-02-04
JP7353973B2 true JP7353973B2 (ja) 2023-10-02

Family

ID=62908746

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019539809A Active JP7353973B2 (ja) 2017-01-19 2018-01-19 Ａｐｏｃ－ｉｉ模倣ペプチド
JP2023100171A Pending JP2023116739A (ja) 2017-01-19 2023-06-19 Ａｐｏｃ－ｉｉ模倣ペプチド

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023100171A Pending JP2023116739A (ja) 2017-01-19 2023-06-19 Ａｐｏｃ－ｉｉ模倣ペプチド

Country Status (14)

Country Link
US (2) US11136372B2 (enExample)
EP (1) EP3571216A4 (enExample)
JP (2) JP7353973B2 (enExample)
KR (1) KR102700862B1 (enExample)
CN (1) CN110831957B (enExample)
AU (1) AU2018210404B2 (enExample)
BR (1) BR112019014707A2 (enExample)
CA (1) CA3050106A1 (enExample)
IL (2) IL268093B2 (enExample)
MX (1) MX2019008529A (enExample)
NZ (1) NZ755599A (enExample)
SG (2) SG11201906422VA (enExample)
TW (2) TWI788323B (enExample)
WO (1) WO2018136803A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018136803A1 (en) 2017-01-19 2018-07-26 The United States Of America, As Represented By The Secretary Departmetn Of Health & Human Services Apoc-ii mimetic peptides
CN117580857A (zh) * 2021-06-23 2024-02-20 美国政府(由卫生和人类服务部的部长所代表) Apoc-ii短模拟肽及使用方法
WO2023215838A1 (en) * 2022-05-05 2023-11-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Short apolipoprotein e mimetic peptides and methods of use
EP4565251A1 (en) * 2022-08-07 2025-06-11 Protean Bio, Inc. Peptides for beta-cell survival and insulin production

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110033518A1 (en) 2008-04-15 2011-02-10 Remaley Alan T Peptides promoting lipid efflux via abca1 and activating a lipoprotein lipase

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US6156727A (en) * 1996-09-05 2000-12-05 Uab Research Foundation Anti-atherosclerotic peptides and a transgenic mouse model of antherosclerosis
MXPA04002848A (es) 2001-09-28 2005-06-06 Esperion Therapeutics Inc Prevencion y tratamiento de restenosis por administracion local de medicamento.
US7220576B2 (en) * 2002-01-07 2007-05-22 Lifesensors, Inc. Methods and compositions for protein expression and purification
CA2512879A1 (en) * 2003-01-17 2004-08-12 Soumya P. Sahoo N-cyclohexylaminocarbonyl benzenesulfonamide derivatives
WO2005058938A2 (en) * 2003-12-15 2005-06-30 The Regents Of The University Of California Helical synthetic peptides that stimulate cellular cholesterol efflux
US7691860B2 (en) * 2004-02-19 2010-04-06 Banyu Pharmaceutical Co., Ltd. Sulfonamide derivatives
US7569546B2 (en) * 2004-07-16 2009-08-04 Trustees Of Tufts College Apolipoprotein A1 mimetics and uses thereof
AU2006263332B2 (en) * 2005-06-29 2012-02-23 Hadasit Medical Research Services & Development Ltd. Protein kinase C inhibitors for prevention of insulin resistance and type 2 diabetes
US20080138284A1 (en) * 2006-09-26 2008-06-12 Lipid Sciences, Inc. Novel Peptides That Promote Lipid Efflux
WO2009097584A1 (en) * 2008-01-30 2009-08-06 Proteogenix, Inc. Maternal serum biomarkers for detection of pre-eclampsia
EP2484692A4 (en) 2009-09-30 2013-03-06 Snu R&Db Foundation MIMETIC APOLIPOPROTEIN A-1-PEPTIDES AND THERAPEUTICS FOR THE TREATMENT OF HYPERLIPIDEMIA AND DISEASES RELATED TO HYPERLIPIDEMIA THEREWITH
BR112015010276A2 (pt) 2012-11-06 2019-10-15 Hoffmann La Roche peptídeos miméticos
WO2018136803A1 (en) 2017-01-19 2018-07-26 The United States Of America, As Represented By The Secretary Departmetn Of Health & Human Services Apoc-ii mimetic peptides
EA201991491A1 (ru) 2017-03-24 2019-12-30 Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сервисис Миметические пептиды apoc-ii

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110033518A1 (en) 2008-04-15 2011-02-10 Remaley Alan T Peptides promoting lipid efflux via abca1 and activating a lipoprotein lipase

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
The Journal of Clinical Investigation，1986年02月，77，520-527
The Journal of Pharmacology and Experimental Therapeutics，2015年02月，352，227-235
The Journal of Pharmacology and Experimental Therapeutics，2016年02月，356，341-353

Also Published As

Publication number Publication date
MX2019008529A (es) 2020-02-07
AU2018210404A1 (en) 2019-08-08
SG10201911974UA (en) 2020-02-27
US20200140522A1 (en) 2020-05-07
NZ755599A (en) 2022-12-23
WO2018136803A1 (en) 2018-07-26
IL279831A (en) 2021-03-01
AU2018210404B2 (en) 2022-01-27
TW202130652A (zh) 2021-08-16
IL268093B1 (en) 2024-03-01
TWI788323B (zh) 2023-01-01
IL268093A (en) 2019-09-26
TW201835097A (zh) 2018-10-01
IL268093B2 (en) 2024-07-01
EP3571216A1 (en) 2019-11-27
SG11201906422VA (en) 2019-08-27
BR112019014707A2 (pt) 2020-04-07
EP3571216A4 (en) 2020-11-04
KR102700862B1 (ko) 2024-08-30
US11827690B2 (en) 2023-11-28
CA3050106A1 (en) 2018-07-26
US20210324043A1 (en) 2021-10-21
JP2020511425A (ja) 2020-04-16
WO2018136803A8 (en) 2019-08-01
US11136372B2 (en) 2021-10-05
JP2023116739A (ja) 2023-08-22
CN110831957B (zh) 2024-02-09
KR20190121305A (ko) 2019-10-25
CN110831957A (zh) 2020-02-21

Similar Documents

Publication Publication Date Title
US11827690B2 (en) ApoC-II mimetic peptides
US20180037610A1 (en) Novel sp-b & sp-c peptides, synthetic lung surfactants, and use thereof
JP2017528437A (ja) アポｅ模倣ペプチド及び血漿コレステロールを取り除くためのより高い効果
JP2020523035A (ja) タウ凝集阻害剤
US11453701B2 (en) Tau aggregation peptide inhibitors
JP2019089834A (ja) アポリポタンパク質模倣体及びその使用
JP7684788B2 (ja) 代謝疾患を治療する組成物と方法
EA042134B1 (ru) МИМЕТИЧЕСКИЕ ПЕПТИДЫ apoC-II
US12016899B2 (en) Compositions comprising Sel1-derived peptides and methods of treatment/prevention of excess oxalate levels and associated conditions/diseases therewith
CN117580857A (zh) Apoc-ii短模拟肽及使用方法
JP6697474B2 (ja) 代謝障害の治療薬としてのデルマトポンチン
US20170305981A1 (en) Synthetic peptides
CN111902158A (zh) 与肺修复有关的方法和组合物

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20200110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20200110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200305

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201218

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201218

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20210506

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20210506

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20210915

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20210915

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20211021

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211102

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20211126

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20211129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20211126

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220330

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220801

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221028

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230220

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230619

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230623

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230821

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230920

R150 Certificate of patent or registration of utility model

Ref document number: 7353973

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150